BRPI0516718A - forma de dosagem de ibuprofeno de liberação modificada - Google Patents

forma de dosagem de ibuprofeno de liberação modificada

Info

Publication number
BRPI0516718A
BRPI0516718A BRPI0516718-3A BRPI0516718A BRPI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A
Authority
BR
Brazil
Prior art keywords
ibuprofen
dosage form
modified release
administration
hours following
Prior art date
Application number
BRPI0516718-3A
Other languages
English (en)
Inventor
Michael Hite
Cathy Federici
Stephen Turner
Alan Brunelle
Original Assignee
Scolr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scolr Pharma Inc filed Critical Scolr Pharma Inc
Publication of BRPI0516718A publication Critical patent/BRPI0516718A/pt
Publication of BRPI0516718B1 publication Critical patent/BRPI0516718B1/pt
Publication of BRPI0516718B8 publication Critical patent/BRPI0516718B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

FORMA DE DOSAGEM DE IBUPROFENO DE LIBERAçãO MODIFICADA. A presente invenção refere-se a uma forma de dosagem sólida para administração oral de ibuprofeno compreendendo uma formulação de liberação modificada de ibuprofeno que provê um efeito de explosão imediato e em seguida uma liberação sustentada de ibuprofeno suficiente para manter níveis sanguíneos de pelo menos 6,4 <109>g/ml durante um período prolongado de pelo menos 8 horas seguindo administração em uma dose única. A forma de dosagem libera ibuprofeno em uma taxa suficiente para inicialmente aplicar uma quantidade eficaz de ibuprofeno dentro de cerca de 2,0 horas seguindo administração. A forma de dosagem então subseqüentemente aplica a quantidade restante de ibuprofeno em uma taxa relativamente constante suficiente para manter um nível de ibuprofeno durante um período de aplicação predeterminado por pelo menos 8 horas.
BRPI0516718A 2004-09-30 2005-09-30 formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco BRPI0516718B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US61493204P 2004-09-30 2004-09-30
US60/614,932 2004-09-30
US68963105P 2005-06-10 2005-06-10
US60/689,631 2005-06-10
US11/238,802 US20060068009A1 (en) 2004-09-30 2005-09-29 Modified release ibuprofen dosage form
US11/238,802 2005-09-29
PCT/US2005/035630 WO2006039692A2 (en) 2004-09-30 2005-09-30 Modified release ibuprofen dosage form

Publications (3)

Publication Number Publication Date
BRPI0516718A true BRPI0516718A (pt) 2008-09-16
BRPI0516718B1 BRPI0516718B1 (pt) 2019-05-14
BRPI0516718B8 BRPI0516718B8 (pt) 2021-05-25

Family

ID=36099442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516718A BRPI0516718B8 (pt) 2004-09-30 2005-09-30 formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco

Country Status (13)

Country Link
US (1) US20060068009A1 (pt)
EP (1) EP1793809B1 (pt)
JP (1) JP2008515802A (pt)
KR (1) KR20070064352A (pt)
AU (1) AU2005292185B2 (pt)
BR (1) BRPI0516718B8 (pt)
CA (1) CA2582150C (pt)
HK (1) HK1107002A1 (pt)
IL (1) IL182144A (pt)
MX (1) MX2007003919A (pt)
NZ (1) NZ554213A (pt)
PL (1) PL1793809T3 (pt)
WO (1) WO2006039692A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20130115250A1 (en) * 2009-05-13 2013-05-09 Wyeth Llc Burst Drug Release Compositions
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP6304896B2 (ja) * 2013-07-30 2018-04-04 ライオン株式会社 錠剤
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
JP6443891B2 (ja) * 2014-01-31 2018-12-26 塩野義製薬株式会社 徐放性製剤
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
CN112168796B (zh) * 2020-09-28 2022-10-25 北京诺康达医药科技股份有限公司 双相缓释系统控制释放的药物缓释制剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3669103D1 (de) * 1986-11-14 1990-04-05 Puetter Medice Chem Pharm Ibuprofen enthaltendes arzneimittel.
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
GB9702392D0 (en) * 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US6592901B2 (en) * 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
EP1444978A1 (en) * 2001-11-13 2004-08-11 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004050025A2 (en) * 2002-11-29 2004-06-17 Forest Laboratories, Inc. Combination of ibuprofen and oxycodone for acute pain relief
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form

Also Published As

Publication number Publication date
NZ554213A (en) 2010-01-29
EP1793809B1 (en) 2012-07-11
US20060068009A1 (en) 2006-03-30
BRPI0516718B8 (pt) 2021-05-25
AU2005292185A1 (en) 2006-04-13
IL182144A (en) 2014-01-30
IL182144A0 (en) 2007-07-24
AU2005292185B2 (en) 2010-06-17
BRPI0516718B1 (pt) 2019-05-14
PL1793809T3 (pl) 2012-12-31
JP2008515802A (ja) 2008-05-15
MX2007003919A (es) 2007-09-07
WO2006039692A2 (en) 2006-04-13
HK1107002A1 (en) 2008-03-28
EP1793809A4 (en) 2010-05-12
CA2582150A1 (en) 2006-04-13
KR20070064352A (ko) 2007-06-20
WO2006039692A3 (en) 2006-06-15
CA2582150C (en) 2014-01-14
EP1793809A2 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
BRPI0516718A (pt) forma de dosagem de ibuprofeno de liberação modificada
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
EA201100304A1 (ru) Система доставки лекарственного средства, содержащего прогестин
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
MX2009011900A (es) Curacion de herida diabetica.
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
Kirschneck et al. Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
BRPI0513186A (pt) composição medicinal para a administração oral
MXPA04004907A (es) Composiciones de acetaminofen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF